PMID- 33835969
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20230822
IS  - 1536-4828 (Electronic)
IS  - 0885-3177 (Print)
IS  - 0885-3177 (Linking)
VI  - 50
IP  - 3
DP  - 2021 Mar 1
TI  - Adverse Events Associated With Therapeutic Endoscopic Retrograde Pancreatography.
PG  - 378-385
LID - 10.1097/MPA.0000000000001769 [doi]
AB  - OBJECTIVES: Data regarding the safety of endoscopic retrograde pancreatography 
      (ERP) are limited compared with biliary endoscopic retrograde 
      cholangiopancreatography. The aim of this study was to determine adverse events 
      (AEs) associated with therapeutic ERP. METHODS: This single-center retrospective 
      study examined consecutive therapeutic ERPs with the primary intention of 
      cannulating the pancreatic duct. Multivariate logistic regression was performed 
      to identify risk factors for AEs. RESULTS: A total of 3023 ERPs were performed in 
      1288 patients (mean age, 50.3 years; 57.8% female) from January 2000 to January 
      2017. Overall AE rate was 18.9% with abdominal pain requiring admission (9.8%) 
      and post-ERP pancreatitis (5.7%) being most common. On multivariate analysis, 
      female sex (adjusted odds ratio [aOR], 2.3; 95% confidence interval [CI], 
      1.9-2.9), acute recurrent pancreatitis (aOR, 5.0; 95% CI, 1.7-15.3), chronic 
      pancreatitis (aOR, 1.8; 95% CI, 1.3-2.6), and pancreatic sphincter of Oddi 
      dysfunction (aOR, 2.1; 95% CI, 1.4-3.3) were associated with an increased risk of 
      overall AEs. Pancreatic sphincterotomy (aOR, 1.9; 95% CI, 1.5-2.4) and 
      therapeutic stenting (aOR, 1.6; 95% CI, 1.2-2.2) also increased the risk of AEs. 
      CONCLUSIONS: Nearly 1 in 5 patients who undergo therapeutic ERP will experience 
      an AE; however, the rates of major AEs, including post-ERP pancreatitis, 
      bleeding, and perforation, are low.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Han, Samuel
AU  - Han S
FAU - Attwell, Augustin R
AU  - Attwell AR
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
FAU - Tatman, Philip
AU  - Tatman P
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
FAU - Edmundowicz, Steven A
AU  - Edmundowicz SA
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
FAU - Hammad, Hazem T
AU  - Hammad HT
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
FAU - Wagh, Mihir S
AU  - Wagh MS
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
FAU - Wani, Sachin
AU  - Wani S
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
FAU - Shah, Raj J
AU  - Shah RJ
AD  - From the Division of Gastroenterology and Hepatology, University of Colorado 
      Anschutz Medical Campus, Aurora, CO.
LA  - eng
GR  - T32 DK007038/DK/NIDDK NIH HHS/United States
GR  - T32 GM007635/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pancreas
JT  - Pancreas
JID - 8608542
SB  - IM
MH  - Adult
MH  - Aged
MH  - Endoscopy, Digestive System/*adverse effects/methods
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Pancreas/*surgery
MH  - Pancreatectomy/*adverse effects/methods
MH  - Pancreatic Ducts/*surgery
MH  - Pancreatitis/diagnosis/etiology
MH  - Postoperative Complications/diagnosis/*etiology
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC8041157
MID - NIHMS1673290
COIS- S.A.E. is an advisory board member for Olympus. H.T.H. is a consultant for 
      Olympus, Medtronic, and Cook Medical. M.S.W. is a Consultant for Boston 
      Scientific and Medtronic. S.W. is a consultant for Boston Scientific, Medtronic, 
      Interpace, and Cernostics. R.J.S. is an Advisory Board Member and Consultant for 
      Boston Scientific and Consultant for Olympus and Cook Medical. The rest of the 
      authors declare no conflict of interest.
EDAT- 2021/04/10 06:00
MHDA- 2022/01/01 06:00
PMCR- 2022/03/01
CRDT- 2021/04/09 17:15
PHST- 2021/04/09 17:15 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - 00006676-202103000-00015 [pii]
AID - 10.1097/MPA.0000000000001769 [doi]
PST - ppublish
SO  - Pancreas. 2021 Mar 1;50(3):378-385. doi: 10.1097/MPA.0000000000001769.